Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is commencing phase 2 of a study designed to investigate its proprietary SPU-21, a novel joint homing peptides targeting rheumatoid arthritis (“RA”). The company has entered into a research agreement that will evaluate the peptide’s method, optimization and binding affinity in human tissue surrounding joints and tendons. Silo Pharma is working with the University of Maryland, Baltimore to advance the development of SPU-21 liposomal joint homing peptides. “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue,” said Silo Pharma CEO Eric Weisblum in the press release. “The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”

To view the full press release, visit https://ibn.fm/0KWSD

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork